WuXi AppTec IPO tops $353m

By Melissa Fassbender contact

- Last updated on GMT

(Image: WuXi AppTec Co., Ltd.)
(Image: WuXi AppTec Co., Ltd.)
The Chinese contract research and development company WuXi AppTec has raised more than $353m in its initial public offering of common stock on the Shanghai Stock Exchange.

WuXi AppTec's​ initial public offering (IPO) of 104,198,600 shares of common stock was offered on the Shanghai Stock Exchange​ at RMB21.60 per share.

This, equivalent to US$3.39 per share, means the IPO has brought in more than $353m.

According to the company, the funds will be used to build and expand its R&D facilities in China, “further strengthening its capabilities and capacities to better serve global customers and partners.”

The Shanghai-headquartered CDMO operates 26 sites globally and branch offices in China, the US, Germany, UK, Japan, Korea, and Israel. 

Dr. Ge Li, chairman and CEO of WuXi AppTec, said in a statement: "I'm deeply grateful for the great confidence and support we have received from the investment community… It allows us to further focus on our mission and accelerate growth of our enabling platform.”

WuXi AppTec has not responded to a request for comment as of publication.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars